Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada

Lisa Maree Williams/Getty Images News

The $5 a share contingent value right in Astrazeneca’s (NASDAQ:AZN) planned $1.1 billion purchase of Icosavax (NASDAQ:ICVX) is based on FDA approval of RSV vaccine candidate IVX-A12 and some sales metrics.

The $4 a share CVR is based on the FDA

ApprovalbasedCanadaCVRDealFDAIcosavaxIVXA12Sales
Comments (0)
Add Comment